DLS invited to participate in the national Friends of Cancer Research (FOCR) HRD Harmonization project
DLS, one of the leading companies in tumor profiling diagnostics, was invited to participate in the national Friends of Cancer Research (FOCR) HRD Harmonization project.
DLS joined a collaborative effort by FOCR to ensure standardization in identifying Homologous Recombination Deficiency (HRD) in cancer and its implications for treatment effectiveness and patient prognosis. Optimized HRD testing will realize the potential of using PARP inhibitor therapy for HRD-positive cancers.
The DLS approach utilizes next-generation sequencing (NGS) data to assess chromosomal structural alterations seen in Homologous Recombination Deficiency. HRD structural analysis is an integral part of the DLS NGS tumor profile.
The FOCR group conducted a comprehensive analysis to understand how HRD is utilized and defined across various test methodologies. Each of the test developers participating in the project was provided with samples to analyze using their respective HRD assay. The findings from this comparative analysis will be instrumental in guiding efforts to harmonize the results, predict treatment outcomes, and predict patient prognosis.
Learn more about our precision medicine progrom.
